Anemia Clinical Trial
Official title:
Clinical Burden of Anemia in Inflammatory Bowel Disease: Role of Iron Deficiency And Iron Replacement Therapy, Observational Study (RIDART-1)
Anemia is the most common extraintestinal manifestation of IBD, occurring in 6 to 74 percent of patients. Most cases of anemia in IBD are due to iron deficiency (IDA) and to anemia of inflammation (AI). Although the ECCO diagnostic criteria for IDA are simple, and iron supplementation represents a cheap and usually effective treatment, many IBD patients with IDA are not properly treated. The inconsistent adherence, by many physicians, to treatment guidelines for IDA in IBD is often motivated by the belief that mild to moderate degrees of anemia may not have a significant impact on the patient's quality of life or do not represent the main clinical problem of the patient, that oral iron supplementation may adversely affect disease activity, and that parenteral iron administration may cause severe side effects. On this basis, we aim to perform a longitudinal, prospective, observational study whose main objective is the determination of the prevalence of anemia in IBD patients in Italy. Secondary objectives of the study are a) to investigate the pathogenesis of anemia in IBD, with a particular focus on the differential diagnosis between IDA and AI, and how disease activity, extension or behavior influence the relative frequency of IDA and AI; b) to verify the adherence to ECCO guidelines for the treatment of IDA in IBD (the proportion of patients with IDA that receive adequate iron supplementation); c) to administer dedicated questionnaires to the patients in order to measure the influence of anemia on fatigue and quality of life among IBD patients.
BACKGROUND
Anemia is the most common extraintestinal manifestation of IBD, occurring in 6 to 74 percent
of patients. This wide range in the prevalence of anemia is related to differences in study
design, in the criteria used to define anemia and to the increasing awareness of anemia in
these patients. According to a recent meta-analysis of European studies involving 2192 IBD
patients, the overall prevalence of anemia in Europe was 27%, ulcerative colitis patients
being less likely to develop anemia than those with Crohn's disease. Therefore, anemia
represents a significant clinical and social burden in IBD management; this is more evident
in southern Europe where the prevalence of anemia is close to 40%. Most cases of anemia in
IBD are due to iron deficiency (IDA) and to anemia of inflammation (AI). Guidelines
concerning the diagnosis and treatment of IDA in IBD have been published by the European
Crohn's and Colitis Organisation. According to present guidelines iron supplementation should
be started when IDA is present or even in the presence of iron deficiency without anemia. A
meta-analysis of iron supplementation studies in IBD-associated IDA found that intravenous
iron is more effective and better tolerated than oral iron supplementation, but the sample
size of the included studies was small; absolute indications for intravenous iron include
severe anemia (haemoglobin <10.0 g/dL) and intolerance or inadequate response to oral iron.
Although the ECCO diagnostic criteria for IDA are simple, and iron supplementation represents
a cheap and usually effective treatment, many IBD patients with IDA are not properly treated.
The inconsistent adherence, by many physicians, to treatment guidelines for IDA in IBD is
often motivated by the belief that mild to moderate degrees of anemia may not have a
significant impact on the patient's quality of life or do not represent the main clinical
problem of the patient, that oral iron supplementation may adversely affect disease activity,
and that parenteral iron administration may cause severe side effects.
RATIONALE
In order to improve the diagnostic and therapeutic work-up of anemia in IBD, it is necessary
to precisely define the prevalence and pathogenesis of anemia in the Italian IBD population
and gain informations about how anemic patients, particularly those with IDA, are usually
managed and followed-up. In addition, since IDA and AI are the most common forms of anemia in
IBD, and both mechanisms often concur to the pathogenesis of anemia in the same subject,
stringent diagnostic criteria to distinguish the three conditions (IDA, AI and coexistence of
IDA and AI) are urgently needed. The differential diagnosis between IDA and AI is often
difficult since inflammation modifies serum ferritin and transferrin saturation (TfSat) that
become unreliable as indicators of iron status. Recently, serum hepcidin concentration has
been identified as a new index of iron status that can be useful to differentiate IDA and AI
in IBD. Hepcidin, a peptide produced by the liver in response to increased iron stores,
inflammation and reduced erythropoietic activity, is the master regulator of body iron
homeostasis and acts by inhibiting iron absorption and iron release from hepatocytes and
macrophages to plasma. The potential role of serum hepcidin determination as a diagnostic
tool in the differential diagnosis of anemia in IBD and in other inflammatory diseases must
be clearly defined. The investigation of these topics is important since a more accurate
pathogenetic diagnosis of anemia in IBD, while preventing the useless and potentially harmful
treatment of AI with iron supplementation, might allow the identification and appropriate
treatment of IDA patients in the presence of inflammation.
STUDY DESIGN
We will perform a longitudinal, prospective, observational study whose aim is the
determination of the prevalence and pathogenesis of anemia in IBD patients. Anemia is defined
according to WHO criteria: Hb <13.0 g/dL for males and Hb <12 g/dL for females. Anemia
work-up should be initiated whenever Hb concentration is below normal and will include the
determination of the laboratory parameters reported in the CRF. A serum ferritin <100 µg/L
and transferrin saturation <20% are required for the diagnosis of isolated IDA and for the
association of IDA and inflammation. We plan to involve at least 60 IG-IBD Centers in this
observational study. We expect to include 2000 anemic patients in the study; approximately 80
to 90% of these patients will have some form of iron deficiency and/or AI. This will allow to
evaluate differences in prevalence of IDA and AI according to gender, age, diagnosis, time
from diagnosis, presence of inflammation, activity, extension and behaviour of the disease,
and to evaluate variables associated with type and severity of anemia in both univariate and
multivariate analysis. Expected duration of subject participation to both the observational
and the therapeutic trials will be 24 weeks; all anemic patients recruited in the study will
undergo screening to investigate the mechanism of anemia, and follow-up evaluation will be
performed at weeks 4, 12 and 24. At follow-up, informations about the treatment of anemia,
fatigue and quality of life must be collected.
OBJECTIVES
Primary endpoint of this observational study is to determine the prevalence of anemia in
Italian patients with IBD. Secondary objectives of the study are a) to investigate the
pathogenesis of anemia in IBD, with a particular focus on the differential diagnosis between
IDA and AI, and how disease activity, extension or behavior influence the relative frequency
of IDA and AI; b) to verify the adherence to ECCO guidelines for the treatment of IDA in IBD
(the proportion of patients with IDA that receive adequate iron supplementation); c) to
administer dedicated questionnaires to the patients in order to measure the influence of
anemia on fatigue and quality of life among IBD patients.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Active, not recruiting |
NCT02101944 -
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 |